Market Cap 5.89M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 153,500
Avg Vol 133,884
Day's Range N/A - N/A
Shares Out 7.44M
Stochastic %K 88%
Beta 0.27
Analysts Strong Buy
Price Target $2.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
SurfTheTicker
SurfTheTicker Oct. 7 at 3:04 AM
$AGMH $BBLG $KTTA $MSN $TBH This has been going huge so far! Watch PRHI as well, that one can be a $1 To $10 stock easily
0 · Reply
FlowRicky
FlowRicky Oct. 5 at 9:34 AM
$KTTA Biotech speculation. Pre-revenue stage. Chart shows high volatility. No clear direction.
0 · Reply
UtahSUV
UtahSUV Sep. 30 at 5:11 AM
$LGVN $KTTA i just want to say fuck you both
0 · Reply
UtahSUV
UtahSUV Sep. 22 at 5:27 PM
$KTTA to zero
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 22 at 12:02 PM
🚨 New Signal ✅ 💊 $KTTA 🗓️ Sep 22, 2025 💵 Entry: $0.7296 🎯 Target (Optional): $0.861 (+18.01%)
0 · Reply
SurfTheTicker
SurfTheTicker Sep. 21 at 10:09 PM
1 · Reply
AttractDontChase
AttractDontChase Sep. 21 at 7:38 PM
$KTTA is a rare small cap biotech trading under $1 with a prior high near $7.50, a tiny float, and real catalysts in motion. With PAS-004 in trials, global expansion, and a stronger advisory board, the setup is rock-bottom undervaluation. If data or sentiment flips, KTTA has the ingredients to be one of those rare names that re rates into the $20$50+ zone.
0 · Reply
AttractDontChase
AttractDontChase Sep. 20 at 1:57 AM
$KTTA is sitting near rock bottom with a tiny market cap, low float, and recent catalysts that could spark a massive re-rating. The company is advancing its PAS-004 clinical trial, expanding internationally, and strengthening its scientific advisory board signaling real biotech momentum. Trading under $1 with a prior high near $7.50, KTTA is deeply undervalued and positioned for asymmetric upside. If trial data surprises, volume surges, and sentiment shifts, this could be one of those rare small-cap biotech names that climbs back into the $20$50+ range over time.
0 · Reply
WallStDecoding
WallStDecoding Sep. 19 at 2:20 AM
$MSN – No dilution, $16M cash, trading way below book value $KTTA – Biotech with bullish daily reversal forming, low float $LDI – Mortgage sector sleeper, rebounding off macro fear lows $TSLA – Holding key trendline, one strong day from breakout $INTC – Undervalued AI hardware play, earnings growth reaccelerating
0 · Reply
Shubeedoo
Shubeedoo Sep. 16 at 1:58 PM
$KTTA $LEXX running. Should/could be a 10 bagger from here. News pending, NVO, LLY?
0 · Reply
Latest News on KTTA
Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 1 year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?


SurfTheTicker
SurfTheTicker Oct. 7 at 3:04 AM
$AGMH $BBLG $KTTA $MSN $TBH This has been going huge so far! Watch PRHI as well, that one can be a $1 To $10 stock easily
0 · Reply
FlowRicky
FlowRicky Oct. 5 at 9:34 AM
$KTTA Biotech speculation. Pre-revenue stage. Chart shows high volatility. No clear direction.
0 · Reply
UtahSUV
UtahSUV Sep. 30 at 5:11 AM
$LGVN $KTTA i just want to say fuck you both
0 · Reply
UtahSUV
UtahSUV Sep. 22 at 5:27 PM
$KTTA to zero
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 22 at 12:02 PM
🚨 New Signal ✅ 💊 $KTTA 🗓️ Sep 22, 2025 💵 Entry: $0.7296 🎯 Target (Optional): $0.861 (+18.01%)
0 · Reply
SurfTheTicker
SurfTheTicker Sep. 21 at 10:09 PM
1 · Reply
AttractDontChase
AttractDontChase Sep. 21 at 7:38 PM
$KTTA is a rare small cap biotech trading under $1 with a prior high near $7.50, a tiny float, and real catalysts in motion. With PAS-004 in trials, global expansion, and a stronger advisory board, the setup is rock-bottom undervaluation. If data or sentiment flips, KTTA has the ingredients to be one of those rare names that re rates into the $20$50+ zone.
0 · Reply
AttractDontChase
AttractDontChase Sep. 20 at 1:57 AM
$KTTA is sitting near rock bottom with a tiny market cap, low float, and recent catalysts that could spark a massive re-rating. The company is advancing its PAS-004 clinical trial, expanding internationally, and strengthening its scientific advisory board signaling real biotech momentum. Trading under $1 with a prior high near $7.50, KTTA is deeply undervalued and positioned for asymmetric upside. If trial data surprises, volume surges, and sentiment shifts, this could be one of those rare small-cap biotech names that climbs back into the $20$50+ range over time.
0 · Reply
WallStDecoding
WallStDecoding Sep. 19 at 2:20 AM
$MSN – No dilution, $16M cash, trading way below book value $KTTA – Biotech with bullish daily reversal forming, low float $LDI – Mortgage sector sleeper, rebounding off macro fear lows $TSLA – Holding key trendline, one strong day from breakout $INTC – Undervalued AI hardware play, earnings growth reaccelerating
0 · Reply
Shubeedoo
Shubeedoo Sep. 16 at 1:58 PM
$KTTA $LEXX running. Should/could be a 10 bagger from here. News pending, NVO, LLY?
0 · Reply
Yoety
Yoety Sep. 16 at 11:04 AM
$KTTA 💪
0 · Reply
Napoliblue
Napoliblue Sep. 13 at 4:22 AM
$KTTA this stock is dead when is the reverse split ? In the September 2025 annual meeting, shareholders approved giving the Board the authority to carry out another reverse stock split at a ratio somewhere between 1-for-2 and 1-for-20, to be executed any time before September 3, 2026, without further shareholder approval.
0 · Reply
Amcollins711
Amcollins711 Sep. 11 at 3:57 PM
$MRKR $KTTA my next two
1 · Reply
GluttonBoy
GluttonBoy Sep. 9 at 2:25 PM
TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play $INTS $SMX $BLMZ $TGL $KTTA watching these
0 · Reply
dustbunnies
dustbunnies Sep. 9 at 8:15 AM
$KTTA have the phase 1 results been announced?
0 · Reply
TraderJay85
TraderJay85 Sep. 8 at 4:08 PM
$NXTT $AEI $KTTA $GYRO Got in early on all these and banked. small losses or big gains. thats it! thats how you make a living off the stock market. get in early, have a plan, and profit. NO discords, NO email lists, or 3 other social media platforms. Just hit the follow and we all make money together! $SWIN is my next one im in heavily on. ill see what sets up towards end of day and post another list.
0 · Reply
BioTuesdays
BioTuesdays Sep. 8 at 3:23 PM
$KTTA announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004 in adult participants with neurofibromatosis type 1 (NF1) should proceed to Cohort 2, 8mg tablet, without modification. https://biotuesdays.com/2025/09/08/pasithea-enrolls-cohort-2-for-trial-of-pas-004-in-nf1-after-src-review/
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 7:40 AM
$KTTA Excellent article that nails exactly where KTTA stands right now. So if you want to update your KTTA knowledge or get acquainted with KTTA, this is a must read. https://beyondspx.com/quote/KTTA/analysis/pasithea-therapeutics-unlocking-macrocyclic-mek-potential-amidst-funding-imperatives-nasdaq-ktta
0 · Reply
ibaian
ibaian Sep. 7 at 5:37 PM
$KTTA Pasithea Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference, discussing ongoing clinical trials for PAS-004 in advanced cancer patients and NF1-associated plexiform neurofibromas.
0 · Reply
ibaian
ibaian Sep. 7 at 5:35 PM
$KTTA Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City, to Monday, September 8, at 5:00 PM Eastern Time.
0 · Reply
TraderJay85
TraderJay85 Sep. 7 at 4:58 PM
$NXTT $GYRO $KTTA $SWIN $RAYA This is what im liking for monday. all look good for the gettin. See everyone 1am PT
1 · Reply
Napoliblue
Napoliblue Sep. 5 at 1:35 AM
$KTTA another reverse stock split coming ? And never ends with Thiago he gets to live a fat life in South Beach, while people lose their ass on this stock . Even the pump into HC Wainright event has no legs it is what is hope for news and get out of jail
0 · Reply